File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prospective study on a novel treatment for leaking cystic bleb: Efficacy and safety of collagen crosslinking

TitleProspective study on a novel treatment for leaking cystic bleb: Efficacy and safety of collagen crosslinking
Authors
KeywordsBleb leak
Crosslinking
Cystic bleb
Filtering bleb
Issue Date2019
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEO
Citation
Clinical and Experimental Ophthalmology, 2019 How to Cite?
AbstractImportance: Management of cystic bleb leak is difficult. It would be essential to look for a method to strengthen the original pathological conjunctiva and reverse bleb leak. Background: To evaluate the long‐term efficacy and safety of collagen crosslinking in patients with leaking cystic bleb. Design: Prospective interventional case series at a university‐based hospital. Participants: Twelve eyes in 12 subjects with late‐onset bleb leak from cystic bleb, without indications for prompt surgical interventions were included. Methods: The subjects underwent crosslinking with 0.1% riboflavin application to bleb surface, followed by ultraviolet irradiation for 30 minutes. The subjects were followed up at baseline and at 1 week, 1 month, 3 months, 6 months post‐treatment and then every 6 months afterwards. Main Outcome Measures: Interval from treatment to cessation of bleb leak, recurrence rate of bleb leak and side effects of treatment. Results: The mean follow‐up after crosslinking was 29.33 ± 12.45 months. Bleb leak subsided in 11 (92%) of 12 patients after a single session of crosslinking, after 1 to 8 weeks (median 3 weeks). Time to leak cessation was significantly correlated with the number of prior glaucoma interventions (R = .71, P = .014). Bleb wall at 3 months was significantly thicker than at baseline (0.70 ± 0.67 vs 0.81 ± 0.62 mm, P = .008). None of the patients experienced any complications. Conclusions and Relevance: Crosslinking achieves resolution of cystic bleb leak which lasts for at least 12 months, without the need of subsequent surgical interventions. Crosslinking is a simple, non‐invasive treatment for bleb leak. It aims to restore the integrity of conjunctiva.
Persistent Identifierhttp://hdl.handle.net/10722/271915
ISSN
2017 Impact Factor: 3.217
2015 SCImago Journal Rankings: 1.335

 

DC FieldValueLanguage
dc.contributor.authorCai, Y-
dc.contributor.authorChoy, BNK-
dc.contributor.authorZhu, MM-
dc.contributor.authorLi, BB-
dc.contributor.authorChan, JCH-
dc.contributor.authorHo, WL-
dc.contributor.authorLai, JSM-
dc.date.accessioned2019-07-20T10:31:59Z-
dc.date.available2019-07-20T10:31:59Z-
dc.date.issued2019-
dc.identifier.citationClinical and Experimental Ophthalmology, 2019-
dc.identifier.issn1442-6404-
dc.identifier.urihttp://hdl.handle.net/10722/271915-
dc.description.abstractImportance: Management of cystic bleb leak is difficult. It would be essential to look for a method to strengthen the original pathological conjunctiva and reverse bleb leak. Background: To evaluate the long‐term efficacy and safety of collagen crosslinking in patients with leaking cystic bleb. Design: Prospective interventional case series at a university‐based hospital. Participants: Twelve eyes in 12 subjects with late‐onset bleb leak from cystic bleb, without indications for prompt surgical interventions were included. Methods: The subjects underwent crosslinking with 0.1% riboflavin application to bleb surface, followed by ultraviolet irradiation for 30 minutes. The subjects were followed up at baseline and at 1 week, 1 month, 3 months, 6 months post‐treatment and then every 6 months afterwards. Main Outcome Measures: Interval from treatment to cessation of bleb leak, recurrence rate of bleb leak and side effects of treatment. Results: The mean follow‐up after crosslinking was 29.33 ± 12.45 months. Bleb leak subsided in 11 (92%) of 12 patients after a single session of crosslinking, after 1 to 8 weeks (median 3 weeks). Time to leak cessation was significantly correlated with the number of prior glaucoma interventions (R = .71, P = .014). Bleb wall at 3 months was significantly thicker than at baseline (0.70 ± 0.67 vs 0.81 ± 0.62 mm, P = .008). None of the patients experienced any complications. Conclusions and Relevance: Crosslinking achieves resolution of cystic bleb leak which lasts for at least 12 months, without the need of subsequent surgical interventions. Crosslinking is a simple, non‐invasive treatment for bleb leak. It aims to restore the integrity of conjunctiva.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEO-
dc.relation.ispartofClinical and Experimental Ophthalmology-
dc.subjectBleb leak-
dc.subjectCrosslinking-
dc.subjectCystic bleb-
dc.subjectFiltering bleb-
dc.titleProspective study on a novel treatment for leaking cystic bleb: Efficacy and safety of collagen crosslinking-
dc.typeArticle-
dc.identifier.emailChoy, BNK: bnkchoy@hku.hk-
dc.identifier.emailChan, JCH: jonochan@hku.hk-
dc.identifier.emailHo, WL: hwl069@hku.hk-
dc.identifier.emailLai, JSM: laism@hku.hk-
dc.identifier.authorityChoy, BNK=rp01795-
dc.identifier.authorityChan, JCH=rp02113-
dc.identifier.authorityLai, JSM=rp00295-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/ceo.13520-
dc.identifier.scopuseid_2-s2.0-85066046356-
dc.identifier.hkuros298533-
dc.publisher.placeAustralia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats